Neuro-endocrine changes as new targets in the drug treatment of congestive heart failure
Related Experiment Videos
1Department of Pharmacotherapy, University of Amsterdam, The Netherlands.
Insights
Newer congestive heart failure (CHF) treatments target detrimental neuro-endocrine systems. Drugs like beta-blockers and ACE-inhibitors offer improved outcomes by counteracting harmful sympathetic nervous system and renin-angiotensin-aldosterone system (RAAS) activation.
Area of Science:
- Cardiology
- Pharmacology
- Neuroendocrinology
Background:
- Classical congestive heart failure (CHF) therapies using inotropic and diuretic agents show limitations.
- Neuro-endocrine compensatory mechanisms in CHF, such as sympathetic nervous system activation and renin-angiotensin-aldosterone system (RAAS) stimulation, are increasingly recognized as detrimental long-term.
- These neuro-endocrine systems interact, exacerbating negative effects in CHF patients.
Purpose of the Study:
- To explore novel therapeutic strategies for CHF targeting detrimental neuro-endocrine processes.
- To evaluate the potential of drugs that counteract sympathetic overactivity and RAAS activation in CHF management.
Main Methods:
- Review of existing literature on CHF pathophysiology and pharmacology.
- Analysis of the roles of sympathetic nervous system and RAAS in CHF progression.
- Identification of drug classes (e.g., beta-blockers, ACE-inhibitors, aldosterone antagonists) targeting these pathways.
Main Results:
- Increased sympathetic activity leads to beta-1 adrenoceptor downregulation in the heart.
- RAAS activation results in elevated renin, angiotensin II, and aldosterone levels.
- ACE-inhibitors demonstrate established benefits in CHF, superior to traditional vasodilators due to RAAS modulation.
Conclusions:
- Targeting neuro-endocrine systems offers a promising approach for managing CHF.
- Selective beta-1 adrenoceptor blockers may improve cardiac function and catecholamine response.
- ACE-inhibitors and aldosterone antagonists effectively counteract RAAS activation, improving CHF outcomes.
Abstract:
The classical therapy of congestive heart failure (CHF) with inotropic agents (digitalis and newer inotropics) and diuretic agents remains unsatisfactory in many cases. More recently it is recognized, that some of the neuro-endocrine compensatory processes associated with CHF are detrimental in the long run, and therefore potentially targets for drug treatment. This holds for the following neuro-endocrine mechanisms: 1) increased activity of the sympathetic nervous system and high plasma catecholamines, accompanied by down-regulation of beta 1- but not beta 2-receptors in the heart; 2) stimulation of the renin-angiotensin-aldosterone system (RAAS), causing higher levels of renin, A II and aldosterone. The detrimental sequelae of both processes are even enhanced by their complex mutual interactions. Drug treatment aiming to reduce or suppress these processes and their negative results is potentially offered by: vasodilators, counteracting vasoconstriction, low dose selective beta 1-adrenoceptor blockers, which will not only impair tachycardia but also up-regulate cardiac beta 1-receptors and hence improve the inotropic response to catecholamines; aldosterone antagonists and ACE-inhibitors counteracting the activated RAAS. The beneficial effect of the ACE-inhibitors in CHF is well established and superior to that of classical vasodilators, since it additionally counteracts the enhanced RAAS activity.